secwatch / observer
8-K filed May 28, 2026, 5:06 PM ET ticker ALLO CIK 0001737287
leadership confidence high sentiment neutral materiality 0.65

Allogene appoints Zachary Roberts as CEO effective July 1, 2026; David Chang becomes non-employee director

Allogene Therapeutics, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Zachary Roberts

President and Chief Executive Officer
ALLO · Allogene Therapeutics, Inc.
Effective
2026-07-01
Filed
May 28, 2026, 5:06 PM ET
the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.
Appointed

David Chang

non-employee director
ALLO · Allogene Therapeutics, Inc.
Effective
2026-07-01
Filed
May 28, 2026, 5:06 PM ET
Dr. Chang will remain on the Board and will become a non-employee director commencing on the Effective Date
Departed

David Chang

President and Chief Executive Officer
ALLO · Allogene Therapeutics, Inc.
Effective
2026-06-30
Successor
Zachary Roberts
Filed
May 28, 2026, 5:06 PM ET
Dr. Chang’s last day of service in these positions will be June 30, 2026.
Role change (interim)

Zachary Roberts

Chief Medical Officer (interim)
ALLO · Allogene Therapeutics, Inc.
Effective
2026-07-01
Filed
May 28, 2026, 5:06 PM ET
Dr. Roberts currently serves as the Company’s Executive Vice President, Research and Development, and Chief Medical Officer and will continue serving as the Company’s Chief Medical Officer on an interim basis following the Effective Date.
Appointed

Zachary Roberts

Class I director
ALLO · Allogene Therapeutics, Inc.
Effective
2026-07-01
Filed
May 28, 2026, 5:06 PM ET
Effective on the Effective Date, Dr. Roberts was also appointed to the Board as a Class I director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Zachary Roberts was appointed as President and Chief Executive Officer at Allogene Therapeutics, Inc..

Action
appointed
Role
President and Chief Executive Officer
Exact text from the filing
the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

David Chang was appointed as non-employee director at Allogene Therapeutics, Inc..

Action
appointed
Role
non-employee director
Exact text from the filing
Dr. Chang will remain on the Board and will become a non-employee director commencing on the Effective Date
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

David Chang resigned as President and Chief Executive Officer at Allogene Therapeutics, Inc..

Action
resigned
Role
President and Chief Executive Officer
Exact text from the filing
Dr. Chang’s last day of service in these positions will be June 30, 2026.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.8

Zachary Roberts changed role as Chief Medical Officer (interim) at Allogene Therapeutics, Inc..

Action
will continue serving
Role
Chief Medical Officer (interim)
Exact text from the filing
Dr. Roberts currently serves as the Company’s Executive Vice President, Research and Development, and Chief Medical Officer and will continue serving as the Company’s Chief Medical Officer on an interim basis following the Effective Date.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Zachary Roberts was appointed as Class I director at Allogene Therapeutics, Inc..

Action
appointed
Role
Class I director
Exact text from the filing
Effective on the Effective Date, Dr. Roberts was also appointed to the Board as a Class I director
View on SEC.gov

Allogene Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-26-245484
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.